Clinical trial of MEDI 5117 as a potential therapy for rheumatoid arthritis.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2017
At a glance
- Drugs WBP-216 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 18 Jan 2017 According to WuXi AppTec media release, an Investigational New Drug (IND) application of WBP216 (MEDI5117) for rheumatoid arthritis (RA) and other autoimmune disorders has been approved by the China Food and Drug Administration (CFDA).
- 31 Mar 2015 New trial record
- 27 Mar 2015 An IND has been accepted for review by the China Food and Drug Administration, according to a WuXi PharmaTech media release.